Swiss American CDMO

Swiss American CDMO

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Swiss American CDMO is a specialized, full-service contract organization focused on the topical dermatology and wound care markets. The company differentiates itself through deep formulation expertise, flexible development models, and an integrated manufacturing environment with significant experience in OTC drugs and topical medical devices. With a client base operating in over 190 countries and a strong track record, including building the EltaMD® brand, it positions itself as a partner for both established and emerging brands seeking to commercialize skin health products.

DermatologyWound Care

Technology Platform

Integrated RID laboratory and cGMP manufacturing facility for topical formulation development, optimization, and production. Capabilities include specialized compounding, flexible filling/packaging, and a state-of-the-art water purification system.

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The growing global demand for specialized topical skin care, OTC drugs, and wound care products presents a significant opportunity.
The trend of brands outsourcing development and manufacturing to reduce costs and accelerate time-to-market further drives growth for focused CDMOs like Swiss American.

Risk Factors

Key risks include client concentration, intense competition in the CDMO space, and stringent regulatory compliance requirements for OTC drug and medical device manufacturing.
Supply chain disruptions for specialized ingredients also pose a material risk to operations and margins.

Competitive Landscape

Swiss American CDMO competes in the topical CDMO space against larger, diversified CDMOs and smaller niche players. Its differentiation lies in its deep, 35+ year formulation heritage in skin/wound care, flexible development models, and integrated services from discovery to commercial packaging for complex regulatory pathways.